Home  /  Resource Library  /  A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia

A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia

Results of a phase II study investigating ibrutinib combined with fludarabine for first line treatment of CLL.